Author Index Volume 15

Alvarez del Buergo, M., 233

Ayalon, D., 25

Bachmann, G.A., 3

Backe, B., 183 Baracchini, P., 199

Berg, G., 71

Bernardini, L., 199

Boulet, M.J., 171

Byrjalsen, I., 39

Capelli, N., 225

Castelo-Branco, C., 113

Christiansen, C., 39

Clausen, H.V., 241

Coope, J., 151

Crona, N., 209

Darj, E., 209

de Cecco, L., 199

De Cooman, S., 17

de Deuxchaisnes, C.N., 17

Devogelaer, J.P., 17

di Stefano, M., 47

Drogenijk, A.C., 101

Duran, M., 113

Eckstein, N., 25

Eshel, A., 25

Feinstein, Y., 25

Felding, C., 241

Ferraiolo, A., 199

Fink, B., 61

Fioretti, P., 225

Foldes, J., 25

Fulcheri, E., 199

Gambacciani, M., 225

Garde, K., 7

Gerbaldo, D., 199

González-Merlo, J., 113

Hammer, M., 71

Hanes, V., 53

Heimer, G., 121

Hernandez, E.R., 233

Heytmanek, G., 53

Hotz, E., 195

Hunskaar, S., 183

Imthurn, B., 195

Isaia, G., 47

Jensen, L.C., 61

Keller, P.J., 195

Kopera, H., 1

La Vecchia, C., 141

Larsen, L.G., 241

Lehert, P., 171

Limor, R., 25 Lindgren, R., 71

Lindhard, A., 61

Loft, A., 241

Marsh, J., 151

Melis, G.B., 225

Metka, M., 53

Meuwissen, J.H.J., 33

Mikkelsen, A.L., 241 Molinatti, G.M., 47

Moret, E., 33

Mussetta, M., 47

Navarro-Morquecho, I., 33

Negri, E., 141

Nilsson, K., 121

Nilsson, S., 209

Obel, E.B., 61

Oddens, B.J., 171

Parazzini, F., 141

Pecchio, F., 47

Pescetto, G., 199

Pouilles, J.M., 217 Pryse-Davies, J., 71

Rekers, H., 101

Revilla, M., 233

Ribot, C., 217

Rico, H., 233

Riis, B.J., 39

Riphagen, F., 101

Risberg, B., 71

Sciolla, A., 47

Sitruk-Ware, R., 129

Solstad, K., 7

Spinetti, A., 225

Statter, M., 25

Steendahl, E., 61

Steinberg, R., 25

Taponeco, F., 225

Thormann, L., 39

Tremollieres, F., 217


Vagman, I., 25

Valkenburg, H.A., 101

van Langen, H., 33

Villa, L.F., 233

Visser, A.P., 171



Subject Index Volume 15

Abrasio, oestrogen/progestogen therapy, curettage, menopause, vaccuum aspiration, 61

Age, oestrogens, skin, collagen, menopause, 113
Androgen decline, male climacteric, middle-aged
men, climacteric, midlife crisis, climacteric
myths, 7

Androgen therapy, male hypogonadism, bone mass, osteodensitometry, 17

Attitude to health, menopause, oestrogens, hormone replacement therapy, 183

Bleeding patterns, placental protein 14, hormone replacement therapy, endometrial response, 39

Bone densitometry, menopause, bone mass, bone mineral content, 233

Bone mass, male hypogonadism, osteodensitometry, androgen therapy, 17

Bone mass, menopause, bone mineral content, bone densitometry, 233

Bone metabolism, GnRH-analogue treatment, safety aspects, calcium homeostasis, 25

Bone mineral content, male hypogonadism, calcitonin, testosterone, bone tissue, 47

Bone mineral content, menopause, bone mass, bone densitometry, 233

Bone tissue, male hypogonadism, bone mineral content, calcitonin, testosterone, 47

Breast cancer, estrogens, progestins, epidemiology, 129

Calcitonin, male hypogonadism, bone mineral content, testosterone, bone tissue, 47

Calcitonin, osteoporosis, ovariectomy, prevention, 225

Calcium homeostasis, GnRH-analogue treatment, safety aspects, bone metabolism, 25

Climacteric myths, male climacteric, middle-aged men, climacteric, androgen decline, midlife crisis, 7

Climacteric, male climacteric, middle-aged men, androgen decline, midlife crisis, climacteric myths, 7

Clinical trial, hysterectomy, perimenopausal, 3 Collagen, oestrogens, skin, age, menopause, 113 Combined transdermal therapeutic systems, menopause, hormone replacement therapy, 195

Compliance, hormone replacement therapy, general practice, 151

Continuous regimen, hormone replacement therapy, oestradiol valerate, cyproterone acetate, lipid metabolism, postmenopause, 53

Curettage, oestrogen/progestogen therapy, menopause, abrasio, vaccuum aspiration, 61

Cyproterone acetate, hormone replacement therapy, continuous regimen, oestradiol valerate, lipid metabolism, postmenopause, 53

Endometrial response, placental protein 14, hormone replacement therapy, bleeding patterns, 39

Endometrium, hormonal replacement therapy, hysteroscopy, hyperplasia, 199

Endometrium, transdermal, estrogen, gestagen, hyperplasia, 71

Endometrium, vaginosonography, oestrogen replacement therapy, 33

Epidemiology, estrogens, progestins, breast cancer, 129

Estrogen, transdermal, gestagen, endometrium, hyperplasia, 71

Estrogens, progestins, breast cancer, epidemiology, 129

General practice, hormone replacement therapy, compliance, 151

Genital prolapse, oestradiol, 241

Genito-urinary tract, menopause, incontinence, 101

Gestagen, transdermal, estrogen, endometrium, hyperplasia, 71

GnRH-analogue treatment, safety aspects, bone metabolism, calcium homeostasis, 25

Hormonal replacement therapy, endometrium, hysteroscopy, hyperplasia, 199

Hormone replacement therapy, compliance, general practice, 151

Hormone replacement therapy, continuous regimen, oestradiol valerate, cyproterone acetate, lipid metabolism, postmenopause, 53

Hormone replacement therapy, menopause, combined transdermal therapeutic systems, 195

Hormone replacement therapy, menopause, oestrogens, attitude to health, 183

Hormone replacement therapy, non-hormonal treatment, tranquillizers, reported use, intercountry variation, 171

Hormone replacement therapy, placental protein 14, endometrial response, bleeding patterns, 39

Hyperplasia, endometrium, hormonal replacement therapy, hysteroscopy, 199

Hyperplasia, transdermal, estrogen, gestagen, endometrium, 71

Hysterectomy, perimenopausal, clinical trial, 3 Hysteroscopy, endometrium, hormonal replacement therapy, hyperplasia, 199

Incontinence, menopause, genito-urinary tract,

Inter-country variation, hormone replacement therapy, non-hormonal treatment, tranquillizers, reported use, 171

Lipid metabolism, hormone replacement therapy, continuous regimen, oestradiol valerate, cyproterone acetate, postmenopause, 53

Lipids, progesterone, postmenopausal, lipoproteins, 209

Lipoproteins, progesterone, postmenopausal, lipids, 209

Low-dose oestradiol, postmenopausal, vaginal atrophy, 121

Male climacteric, middle-aged men, climacteric, androgen decline, midlife crisis, climacteric myths, 7

Male hypogonadism, bone mass, osteodensitometry, androgen therapy, 17

Male hypogonadism, bone mineral content, calcitonin, testosterone, bone tissue, 47

Menopause, bone mass, bone mineral content, bone densitometry, 233

Menopause, hormone replacement therapy, combined transdermal therapeutic systems, 195

Menopause, incontinence, genito-urinary tract, 101

Menopause, oestrogen/progestogen therapy, curettage, abrasio, vaccuum aspiration, 61

Menopause, oestrogens, attitude to health, hormone replacement therapy, 183 Menopause, oestrogens, skin, collagen, age, 113 Menopause, risk factors, reproductive factors, 141

Middle-aged men, male climacteric, climacteric, androgen decline, midlife crisis, climacteric myths, 7

Midlife crisis, male climacteric, middle-aged men, climacteric, androgen decline, climacteric myths, 7

Non-hormonal treatment, hormone replacement therapy, tranquillizers, reported use, intercountry variation, 171

Oestradiol valerate, hormone replacement therapy, continuous regimen, cyproterone acetate, lipid metabolism, postmenopause, 53

Oestradiol, genital prolapse, 241

Oestrogen replacement therapy, vaginosonography, endometrium, 33

Oestrogen/progestogen therapy, curettage, menopause, abrasio, vaccuum aspiration, 61

Oestrogens, menopause, attitude to health, hormone replacement therapy, 183

Oestrogens, skin, collagen, age, menopause, 113 Oral hormone replacement therapy, osteoporosis, prevention, 217

Osteodensitometry, male hypogonadism, bone mass, androgen therapy, 17

Osteoporosis, ovariectomy, calcitonin, prevention, 225

Osteoporosis, prevention, oral hormone replacement therapy, 217

Ovariectomy, osteoporosis, calcitonin, prevention, 225

Perimenopausal, hysterectomy, clinical trial, 3 Placental protein 14, hormone replacement therapy, endometrial response, bleeding patterns, 39

Postmenopausal, low-dose oestradiol, vaginal atrophy, 121

Postmenopausal, progesterone, lipids, lipoproteins, 209

Postmenopause, hormone replacement therapy, continuous regimen, oestradiol valerate, cyproterone acetate, lipid metabolism, 53

Prevention, osteoporosis, oral hormone replacement therapy, 217

Prevention, osteoporosis, ovariectomy, calcitonin, 225

Progesterone, postmenopausal, lipids, lipoproteins, 209

Progestins, estrogens, breast cancer, epidemiology, 129 Reported use, hormone replacement therapy, non-hormonal treatment, tranquillizers, inter-country variation, 171

Reproductive factors, menopause, risk factors, 141

Risk factors, menopause, reproductive factors, 141

Safety aspects, GnRH-analogue treatment, bone metabolism, calcium homeostasis, 25 Skin, oestrogens, collagen, age, menopause, 113

Testosterone, male hypogonadism, bone mineral content, calcitonin, bone tissue, 47

Tranquillizers, hormone replacement therapy, non-hormonal treatment, reported use, intercountry variation, 171

Transdermal, estrogen, gestagen, endometrium, hyperplasia, 71

Vaginal atrophy, low-dose oestradiol, postmenopausal, 121

Vaginosonography, endometrium, oestrogen replacement therapy, 33